Skip to main content

SYSTEMATIC REVIEW article

Front. Med.
Sec. Dermatology
Volume 11 - 2024 | doi: 10.3389/fmed.2024.1401685
This article is part of the Research Topic Advances in Cutaneous Microbial Infections View all 4 articles

Prevalence of Paucibacillary Cases of Leprosy in Brazil: A 20-year systematic review and meta-analysis

Provisionally accepted
Bruna E. Brito Gonçalves Bruna E. Brito Gonçalves 1André Matheus P. Raiol André Matheus P. Raiol 1Ana Vitória C. Brito Ana Vitória C. Brito 1Marcos Jessé A. Silva Marcos Jessé A. Silva 2Daniele M. Sardinha Daniele M. Sardinha 2*Karla Valéria B. Lima Karla Valéria B. Lima 3Luana Nepomuceno G. Lima Luana Nepomuceno G. Lima 3
  • 1 Universidade da Amazônia, Belém, Pará, Brazil
  • 2 Universidade do Estado do Pará, Belem, Para, Brazil
  • 3 Evandro Chagas Institute, Ananindeua, Brazil

The final, formatted version of the article will be published soon.

    Leprosy is a chronic infectious disease caused by the agent Mycobacterium leprae, characterized by its high disabling power. Data points to Brazil being the second country with the highest number of cases in the world, behind only India, representing a major challenge for public health. This work aims to determine the prevalence of paucibacillary (PB) cases in relation to leprosy cases in Brazil, using data published in the literature. This is a systematic review and meta-analysis carried out with studies from the last 20 years, being developed based on the Preferred Reporting Items for Systematic Review and Meta-analyzes (PRISMA). The search was carried out in the databases: PUBMED, SciELO, LILACS (via VHL) and Science Direct in October 2023, using the following descriptors (((“Brazil” [Mesh]) AND (“Leprosy, paucibacillary” [Mesh])) AND “Epidemiology” [Mesh]), in English, Portuguese and Spanish. Original studies of the analytical case-control, cohort, cross-sectional, epidemiological types were selected, as well as articles with satisfactory information for numerical extraction with separate data on the paucibacillary and multibacillary clinical forms. The methodological quality assessment followed the JBI critical appraisal checklist. Statistical analysis was performed using the Comprehensive Meta-Analyses-CMA software, version 3.0 (Biostat, Engewood, NJ, USA). The meta-analysis of the 48 studies obtained a paucibacillary prevalence rate in Brazil of 50.5% or 0.505 (95% CI = 0.502 - 0.509). The differences in the analyzes were statistically significant (Q-value 4302.681; df 47; I 98.905), with a high heterogeneity value evidenced by I² (98.905). This analysis demonstrated that the frequency in the Midwest region was the highest and the South region was the lowest (21.4%). Begg's (Kendall Tau p = 0.35) and Egger's tests (p= 0.20) were performed, in which no high publication bias was noted. Subgroup analysis indicated that paucibacillary cases varied from region to region, with the Midwest region having the highest prevalence and the South region having the lowest. The results stand out significantly for the research gaps that investigate PB cases, requiring more research aimed at investigating the paucibacillary clinical form that can contribute to the early diagnosis of leprosy.

    Keywords: Brazil, Leprosy, Paucibacillary, Mycobacterium leprae, Epidemiology

    Received: 15 Mar 2024; Accepted: 11 Oct 2024.

    Copyright: © 2024 Brito Gonçalves, Raiol, Brito, Silva, Sardinha, Lima and Lima. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Daniele M. Sardinha, Universidade do Estado do Pará, Belem, 66050-540, Para, Brazil

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.